Introduction/Background Epithelial ovarian cancer (EOC) is the most ominous tumor of gynecological cancers due to its poor early detection rate and unfavorable prognosis. To date, there is no reliable screening method for the diagnosis of ovarian cancer at an early stage. MiRNAs are small non-coding RNA molecules, and their main function is to downregulate gene expression. The present study compared the serum miRNA1181 and miRNA4314 levels in patients with EOC and healthy controls to measure the diagnostic and prognostic value as candidate biomarkers.
Methodology We extracted serum samples from a total of 135 participants (69 patients with EOC and 66 healthy controls) at the Department of Gynecologic Oncology between September 2018 and December 2019. Relative expressions of miRNA1181 and miRNA4314 were measured by quantificational real-time polymerase chain reaction assay (qRT-PCR).
Results Of the 69 patients with EOC, 15 were stage I, four were stage II, 35 were stage III, and 15 were stage IV (according to FIGO classification). The median OS was 31.9 months (range 0.9–42.1) and the median DFS was 20.4 months (range 0.9–39.0)The present study revealed that both serum miRNA 1181 and miRNA 4314 levels in patients with EOC were dramatically increased compared to healthy controls with p<0.001 for each marker. In addition, there was a significant relationship between miRNA 1181 and miRNA 4314 overexpressions and the stage and prognosis of the disease. Finally, patients with high expression levels of miRNA 1181 and miRNA 4314 had significantly shorter survival rates than those with low expression levels.
Conclusion The current study proposed that serum miRNA1181 and miRNA4314 could discriminate the EOC patients from healthy controls. In addition, both miRNA1181 and miRNA4314 may be predictive biomarkers for ovarian cancer prognosis. Further studies are needed to confirm the findings of the present study.
Disclosures We declared that we have no conflict of interest
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.